IL-2 increased RANTES production and CD25 expression in cultured PBMCs only from antiretroviral treated HIV-1+ patients with detectable viral loads

Int Immunopharmacol. 2006 Jun;6(6):1034-8. doi: 10.1016/j.intimp.2006.01.002. Epub 2006 Feb 3.

Abstract

In order to better understand the possible beneficial effects of intermittent IL-2 treatment as complement of antiretroviral therapy in HIV-1+ patients, we have measured the levels of RANTES in the supernatants and the CD25 expression in cultured PBMCs obtained from HIV-1+ individuals in presence of IL-2. The results showed a significant increases in RANTES production and in the expression of CD25+ in the cultures with IL-2 of PBMC obtained from HIV-1+ patients with a detectable viral load in comparison with both, HIV-1+ patients with no detectable viral loads and with healthy individuals. These results suggest that therapeutic IL-2 administered in addition to highly active anti-retroviral therapy (HAART) may contribute to increase the effect of this therapy by rising both RANTES production and CD25 expression only in HIV-1+ patients with detectable viral loads.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / analysis
  • Antigens, CD / metabolism
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / metabolism
  • CD4-Positive T-Lymphocytes / virology
  • Cells, Cultured
  • Chemokine CCL5 / metabolism*
  • HIV Infections / blood*
  • HIV Infections / drug therapy
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • Humans
  • Interleukin-2 / pharmacology*
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / metabolism
  • Leukocytes, Mononuclear / virology
  • RNA, Viral / blood
  • Receptors, Interleukin-2 / analysis
  • Receptors, Interleukin-2 / metabolism*
  • Viral Load*

Substances

  • Antigens, CD
  • Chemokine CCL5
  • Interleukin-2
  • RNA, Viral
  • Receptors, Interleukin-2